Phase 1 Epstein Barr Virus Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
Epstein Barr Virus
ModernaTX, Inc.120 enrolled2 locationsNCT07478952
Recruiting
Phase 1
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Cytomegalovirus InfectionsImmune DeficiencyBK Virus Infection+2 more
Columbia University18 enrolled1 locationNCT06926894
Completed
Phase 1
Infusion of virus specific immune cells in patients at the first sign of virus infection after a blood or bone marrow transplant who have received less than 7 days of anti-viral treatment.
Cytomegalovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationAdenovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationEpstein Barr Virus reactivation or infection following allogeneic blood or marrow stem cell transplantation
Western Sydney Local Health District31 enrolled3 locationsACTRN12618000343202